<DOC>
	<DOCNO>NCT00589667</DOCNO>
	<brief_summary>The purpose study determine combination 2 chemotherapy drug call pemetrexed gemcitabine might effective treatment head neck squamous cell cancer . The researcher want find effect , good and/or bad , treatment head neck cancer .</brief_summary>
	<brief_title>A Phase II Study Pemetrexed Plus Gemcitabine Metastatic/Recurrent Head Neck Cancer ( HNSCC )</brief_title>
	<detailed_description>Pemetrexed ( 500 mg/m2 ) gemcitabine ( 1250 mg/m2 ) give together Days 1 15 28 day cycle patient recurrent metastatic head neck squamous cell carcinoma ( HNSCC ) . Patients receive 2 prior chemotherapy regimens recurrent/metastatic disease set . Vitamin B12 folate supplementation administer per standard guideline pemetrexed chemotherapy . The primary endpoint objective radiologic response rate . Radiologic image evaluable disease take place every 2 cycle . Patients may remain study progression disease unacceptable toxicity .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patients must microscopically confirm epidermoid/squamous cell carcinoma ( HNSCC ) oral cavity , pharynx , larynx , paranasal sinus , head/neck squamous cell carcinoma unknown primary . Patients must recurrent metastatic disease amenable curativeintent therapy surgery radiation . No 2 prior cytotoxic therapy recurrent metastatic disease set permit . Patients must least 18 year age . Karnofsky Performance status must ≥ 70 % . Disease must measurable RECIST criterion . At least 4 week must elapse previous radiation therapy . Patient must recover acute toxic effect treatment prior study enrollment . Prior radiation therapy ≤ 25 % bone marrow allow . Prior radiation whole pelvis and/or brain allow . Adequate organ function Patients childbearing potential must negative test pregnancy time enrollment base urine serum pregnancy test . Patients must agree use reliable method birth control 3 month follow last dose study drug . Patient must reside geographic proximity MSKCC adequate followup treatment , per investigator discretion . Patients must sign informed consent document . Previous exposure pemetrexed ( Alimta ) gemcitabine ( Gemzar ) . Pregnancy breastfeed . Serious concomitant systemic disorder ( example , active infection ) , opinion investigator , would compromise safety patient compromise patient 's ability complete study . History brain metastasis . Inability unwillingness take folic acid , vitamin B12 supplementation , dexamethasone . Patients exclude unable hold use nonsteroidal antiinflammatory agent ( NSAIDS ) short elimination half life</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Head Neck Cancer</keyword>
	<keyword>GEMCITABINE</keyword>
	<keyword>PEMETREXED</keyword>
	<keyword>ALTIMA</keyword>
	<keyword>epidermoid/squamous cell</keyword>
	<keyword>carcinoma</keyword>
	<keyword>pharynx</keyword>
	<keyword>larynx</keyword>
	<keyword>paranasal sinus</keyword>
	<keyword>head/neck squamous cell carcinoma</keyword>
</DOC>